학술논문
Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials
Document Type
Artikel
Author
Bergh, J; Pritchard, KI; Swain, S; Cameron, D; Albain, K; Anderson, S; Arriagada, R; Bartlett, J; Bergsten-Nordstrom, E; Bliss, J; Bradley, R; Brain, E; Braybrooke, J; Carey, L; Clarke, M; Coleman, R; Cuzick, J; Davidson, N; Del Mastro, L; Di Leo, A; Dignam, J; Dodwell, D; Dowsett, M; Duane, F; Ejlertsen, B; Francis, P; Gelber, R; Gnant, M; Goetz, M; Goodwin, P; Gray, R; Halpin-Murphy, P; Hayes, D; Hill, C; Jagsi, R; Janni, W; Liu, Z; Loibl, S; MacKinnon, E; Mamounas, E; Mannu, G; Martin, M; McGale, P; Mukai, H; Nekljudova, V; Norton, L; Ohashi, Y; Pan, H; Peto, R; Piccart, M; Pierce, L; Poortmans, P; Raina, V; Rea, D; Regan, M; Robertson, J; Rutgers, E; Slamon, D; Spanic, T; Sparano, J; Steger, G; Taylor, C; Tang, G; Toi, M; Tutt, A; Viale, G; Wang, X; Whelan, T; Wilcken, N; Wolmark, N
Source
The Lancet. Oncology. 22(8):1139-1150
Subject
Language
English
English
English
ISSN
1474-5488